Retraction notice to "Use of ivermectin in the treatment of Covid-19: A pilot trial" [Toxicol. Rep. 8 (2021) 505-510]

Affiliations

¹ Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
² Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461 Bronx, NY, United States.
³ University Hospital of the Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
⁴ Department of Genetics and Evolution, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.

Henrique Pott-Junior et al. Toxicol Rep. 2022.

. 2022 May 2:9:1023.

doi: 10.1016/j.toxrep.2022.04.009. eCollection 2022.

¹ Department of Medicine, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
² Department of Molecular Pharmacology, Albert Einstein College of Medicine, 10461 Bronx, NY, United States.
³ University Hospital of the Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.
⁴ Department of Genetics and Evolution, Federal University of São Carlos (UFSCar), 13565-905 São Carlos, São Paulo, Brazil.

Abstract

[This retracts the article DOI: 10.1016/j.toxrep.2021.03.003.].

Use of ivermectin in the treatment of Covid-19: A pilot trial.
Pott-Junior H, Paoliello MMB, Miguel AQC, da Cunha AF, de Melo Freire CC, Neves FF, da Silva de Avó LR, Roscani MG, Dos Santos SS, Chachá SGF. Pott-Junior H, et al. Toxicol Rep. 2021;8:505-510. doi: 10.1016/j.toxrep.2021.03.003. Epub 2021 Mar 9. Toxicol Rep. 2021. Retraction in: Toxicol Rep. 2022 May 02;9:1023. doi: 10.1016/j.toxrep.2022.04.009. PMID: 33723507 Free PMC article. Retracted.

ESCMID COVID-19 living guidelines: drug treatment and clinical management.
Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Zollner-Schwetz I, Rodríguez-Baño J. Bartoletti M, et al. Clin Microbiol Infect. 2022 Feb;28(2):222-238. doi: 10.1016/j.cmi.2021.11.007. Epub 2021 Nov 22. Clin Microbiol Infect. 2022. PMID: 34823008 Free PMC article.
Correction: Awad et al. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. Pharmaceuticals 2022, 15, 1068.
Awad H, Hassan B, Dweek S, Aboelata Y, Rawas-Qalaji M, Ahmed IS. Awad H, et al. Pharmaceuticals (Basel). 2024 Aug 22;17(8):1100. doi: 10.3390/ph17081100. Pharmaceuticals (Basel). 2024. PMID: 39204208 Free PMC article.
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.
Chavda VP, Gajjar N, Shah N, Dave DJ. Chavda VP, et al. Eur J Med Chem Rep. 2021 Dec;3:100013. doi: 10.1016/j.ejmcr.2021.100013. Epub 2021 Oct 22. Eur J Med Chem Rep. 2021. PMID: 36575695 Free PMC article. Review.